COVID-19

Our primary concern is the safety of all our study participants and minimising any additional strain on our clinical sites and staff.

The COVID-19 pandemic is affecting people and health services around the world. Our primary concern is the safety of all our study participants and minimising any additional strain on our clinical sites and staff. We are working closely with our clinical sites and partner organisations to find ways of doing this. Please contact the relevant trial team via the trial email address if you have questions about what this means for a specific study.

Latest News and Updates

Showing RESPECT for trial participants

Sharing trial results with participants using a printed summary, sent by post, in addition to webpages, improves participants’ satisfaction with how the results are shared.

18 Oct

Advanced bowel cancer trial results from FOCUS4: A promising new drug, and treatment breaks

A new drug has shown promise in delaying the time to the disease getting worse in some bowel cancer patients whose cancer has spread elsewhere in the body.

20 Sep

Abiraterone alongside standard therapy helps men with high-risk prostate cancer to live longer

Results from the STAMPEDE trial were presented at the European Society for Medical Oncology Congress 2021

20 Sep

Spotlight on ESMO

The unit had a great presence at EMSO this year with STAMPEDE, FOCUS4 and TRISST all showcasing new results over the weekend

20 Sep

Our Research Themes

Cancer

Innovative clinical trial design and meta-analysis extending beyond the boundaries of single cancer types

Infections

Major international clinical trials answering questions of global public health significance

Methodology

Development of methods with direct impact on the design, conduct and analysis of studies

Other Research & Policy

This section will capture projects outside the current QQR themes

Our Latest Tweets

MRC CTU at UCL MRCCTU

#Publication - Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial Read it #OpenAccess in @TheLancet https://t.co/gyPTxAShyM

10h
MRC CTU at UCL MRCCTU

#Publication - Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine Read it #OpenAccess in @NEJM https://t.co/gRhAPZvPDj

Oct 21
MRC CTU at UCL MRCCTU

We're looking for a trial manager! This is an exciting opportunity to work across several trials in cancer and infections. The deadline is Friday night ⏳ Apply now 👇 https://t.co/20xALyT28C. Closing date 22nd October. Apply! https://t.co/PxUd8kddoO

Oct 20